Alaska Clinical Research Center

Alaska Clinical ResearchCenter
Alaska Clinical Research Center, LLC (ACRC) is an educational and research affiliate of Alaska Urological Institute, APC. It is a separate site and entity founded by a team of urologists dedicated to conducting clinical research trials in urology.

Our primary objective is to provide optimal patient care by giving patients access to a broad spectrum of treatment alternatives, and greater understanding of new therapies.
For Medical Professionals

All Research Studies (on ClinicalTrials.gov)

Clinical Research Experience

Therapeutic Areas:

  • Urology
  • Urogynecology
  • Urologic Oncology
  • Nephrology
  • Sexual Dysfunction

Our research is specialized to any of our therapeutic specialties, and encompass clinical trials in all phases of study. (Phases II, III, and IV).

  • Erectile Dysfunction
  • Hypogonadism
  • Prostate Cancer
  • Prostatitis
  • Benign Prostatic Hypertrophy (BPH)
  • Pyelonephritis / Urinary Tract Infections
        - complicated & uncomplicated
  • Bladder Cancer
  • Urolithiasis
  • Urinary Incontinence
  • Interstitial Cystitis

Our center has worked with the following:

CRO’s:
PPD Development, Quintiles, Covance, Phoenix International, Kendle, The Phoenix, i3 Research, Inc., ILEX Oncology, Diagnostic Oncology

For Patients
Browse the active studies below to learn about eligibility for patient participation.
Study of Immunotherapy to Treat Advanced Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: placebo + docetaxel/prednisone; Drug: dasatinib + docetaxel/prednisone
Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: TAK-700; Drug: Docetaxel; Drug: Prednisone
A Study in Men With Benign Prostatic Hyperplasia Eli Lilly
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Condition: Benign Prostatic Hyperplasia
Interventions: Drug: LY500307
Drug: Placebo
Febuxostat Versus Allopurinol or Placebo in Subjects With Hyperuricosuria and Calcium Oxalate Stones Takeda Global Research & Development, Inc
A Multicenter, Randomized, Double-Blind, Placebo and Allopurinol Controlled, Phase 2 Study to Evaluate Febuxostat in the Medical Management of Subjects With Hyperuricosuria and Calcium Oxalate Stones
Condition: Hyperuricosuria
Kidney Stones
Interventions: Drug: Febuxostat
Drug: Allopurinol
Drug: Placebo
Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Light Sciences Oncology
A Phase 1 Study to Evaluate the Safety and Effectiveness of Using the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Who Are Candidates for Interventional Therapy
Condition: Benign Prostatic Hyperplasia
Lower Urinary Tract Symptoms
Interventions: Drug: Talaporfin sodium
Procedure: Placement of device in prostate urethra
Device: Transurethral illumination with light emitting diodes (Litx™ BPH Device)

Phase 3 Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant for Noninvasive Bladder Cancer Spectrum Pharmaceuticals

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer.
Active, but closed to further enrollment
Condition: Bladder Cancer
Interventions: Drug: EOquin® (Apaziquone)
Efficacy Study of ABR-215050 to Treat Prostate Cancer Active Biotech

Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: ABR-215050, tasquinimod
Drug: Placebo
The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease Auxilium Pharmaceuticals, Inc.
Phase 3 study will start in Fall, 2010-05-10
Condition:  
Interventions: